Side-by-side comparison of AI visibility scores, market position, and capabilities
All-in-one digital marketing platform with $350M revenue; keyword research, competitive intelligence, and SEO tools for 1M+ users competing with Ahrefs for marketer mindshare.
Semrush is an all-in-one digital marketing platform providing SEO tools, competitive intelligence, PPC research, social media analytics, and content marketing tools for marketers, SEO professionals, and digital agencies. Listed on NYSE (NYSE: SEMR) and headquartered in Boston, Massachusetts (with major operations in St. Petersburg, Russia), Semrush generates approximately $350 million in annual revenue and serves over 1 million users with a database of 25+ billion keywords and competitive data on 800 million+ domains.\n\nSemrush's core product is its keyword research and competitive analysis engine — entering any domain shows its organic search rankings, estimated traffic, top keywords, and backlink profile, enabling marketers to understand their competitors' SEO strategies. The platform includes position tracking (monitoring keyword rankings over time), site auditing (identifying technical SEO issues), backlink analysis, and content optimization tools. The advertising research module shows competitors' PPC ad history, spending estimates, and landing pages.\n\nIn 2025, Semrush competes in the SEO and digital marketing intelligence market against Ahrefs (the other leading SEO platform), Moz, SpyFu, and Similarweb (traffic analytics). The two dominant platforms — Semrush and Ahrefs — have been engaged in continuous feature expansion as each adds tools beyond core keyword research into broader marketing analytics. Semrush has invested in AI tools for content creation and optimization. The 2025 strategy focuses on Semrush AI (AI writing and content generation tools), expanding into broader digital marketing workflow automation, and growing its enterprise segment with agency and brand team subscriptions.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.